Latest Breaking News On - Dsign catalyst - Page 1 : vimarsana.com

5,000 patients treated with OssDsign Catalyst® in the U.S.

OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals

OssDsign awarded long-term agreement with Premier, Inc.

OssDsign awarded long-term agreement with Premier, Inc.

OssDsign AB (publ) publishes year-end report 2023

12-month data from the clinical study of OssDsign Catalyst™ published in Biomedical Journal of Scientific & Technical Research

Uppsala, January 24, 2024. OssDsign AB (publ.) today announces that the previously communicated outstanding 12-month results from the clinical study TOP FUSION have been published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research. The results show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with the novel nanosynthetic bone graft OssDsign Catalyst.

Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product

OssDsign reports exceptional data from the clinical study TOP FUSION

OssDsign reports exceptional data from the clinical study TOP FUSION

Uppsala, January 9, 2024. OssDsign AB today announces that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 %...

Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93%...